RxDoctor Payments Data

Charles Christie

Physician Assistant · Holdrege, NENPI 1083650790

Payments from drug & device makers

$1,189in general payments, 2019–2025

Across 86 payments — averaging $13.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$573
  • Novo Nordisk$89
  • AstraZeneca$85
  • Astellas Pharma US Inc$84
  • Amgen$62
  • Otsuka America Pharmaceutical, Inc.$62
  • plus $234 from 10 others

What the payments were for

  • Food & beverage$1,189100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,189 in reported general payments places this provider in the 70th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$303,703
Medicare patients
567
Services billed
14,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol163$111,672
JardianceEmpagliflozin131$96,850
OzempicSemaglutide78$77,405
EliquisApixaban107$70,810
Soliqua 100-33Insulin Glargine/Lixisenatide60$58,773
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$54,883
JanuviaSitagliptin Phosphate53$42,274
TrulicityDulaglutide43$41,491
XareltoRivaroxaban54$38,647
LinzessLinaclotide61$34,650
ProliaDenosumab18$33,647
Tresiba Flextouch U-100Insulin Degludec60$33,041
Hysingla ErHydrocodone Bitartrate22$23,653
Tresiba Flextouch U-200Insulin Degludec29$18,766
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$18,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$85$132,176222 claims
Boehringer IngelheimJardiance, Spiriva Respimat$17$106,449147 claims
Novo NordiskOzempic$89$77,40578 claims
PfizerEliquis$50$70,810107 claims
GSKTrelegy Ellipta, Shingrix$12$67,645140 claims
AbbVieLinzess, Restasis$573$41,86075 claims
Lilly USA, LLCTrulicity$33$41,49143 claims
AmgenProlia$62$33,64718 claims
Astellas Pharma US IncMyrbetriq$84$15,41247 claims
NovartisEntresto$30$9,54416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Holdrege

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →